CD274 and neoplasm: Various clinical findings have shown that HER2 expressing breast cancer cells in the tumor microenvironment utilize the PD-1/PD-L1 dominant immune checkpoint pathway to down regulate anti-tumor immune cells function and evade immune cells mediated tumor eradication (50, 51).